SHORT COMMUNICATION

Experts’ preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS)

Charlotte Beaudart1,2 · Jürgen M. Bauer3 · Francesco Landi4 · Olivier Bruyère1 · Jean-Yves Reginster1 · Mickael Hiligsmann2 · ESCEO Working Group on Sarcopenia, Sarcopenia Interest Group of the EUGMS

Received: 5 December 2020 / Accepted: 11 January 2021 © The Author(s) 2021

Abstract

Background and aims To assess experts’ preference for sarcopenia outcomes.

Methods A discrete-choice experiment was conducted among 37 experts (medical doctors and researchers) from different countries around the world. In the survey, they were repetitively asked to choose which one of two hypothetical patients suffering from sarcopenia deserves the most a treatment. The two hypothetical patients differed in five pre-selected sarcopenia outcomes: quality of life, mobility, domestic activities, fatigue and falls. A mixed logit panel model was used to estimate the relative importance of each attribute.

Results All sarcopenia outcomes were shown to be significant, and thus, important for experts. Overall, the most important sarcopenia outcome was falls (27%) followed by domestic activities and mobility (24%), quality of life (15%) and fatigue (10%).

Discussion and conclusion Compared to patient’s preferences, experts considered falls as a more important outcome of sarcopenia, while the outcomes fatigue and difficulties in domestic activities were considered as less important.

Keywords Discrete-choice experiment · Sarcopenia · Outcomes

Introduction

Sarcopenia, defined by the European Working Group on Sarcopenia in Older People (EWGSOP2) [1] as a loss of muscle strength combined with a loss of muscle mass, is now recognized to engender multiple health consequences, both at the individual as well as the societal level [2]. Within a patient-centered care approach, Hiligsmann et al. conducted, in 2019, a discrete-choice experiment (DCE) [3] among 216 sarcopenic patients from 6 European countries to identify the most important outcomes for patients. Results highlighted decreased mobility and difficulties with domestic activities as the two most important sarcopenia-related outcomes for patients.

Besides the patients’ point of view, assessing the preferences of experts (including healthcare professionals) for sarcopenia outcomes would be interesting, especially as discordance in preferences between patients and professionals
for healthcare observations have been regularly observed [4]. Particularly for outcomes preferences, it has been shown, for example, that healthcare providers and patients could be concordant on the importance of outcomes such as quality of life but discordant on mortality as a relevant outcome, the latter being systematically rated as much more important by healthcare providers than by patients [4, 5]. DCE studies provide an excellent opportunity to determine whether there is concordance of preferences between patients and health care providers. The preferences of healthcare professionals for specific outcomes may exert a relevant impact on the management of health resources, e.g., sarcopenic patient care.

This study aimed, therefore, to assess experts’ preference for sarcopenia outcomes through a DCE, and to compare experts’ preferences to patients’ preferences, which were identified by the previous study.

### Methods

In the present study, we used the same DCE as was used to elicit patients’ preferences for sarcopenia outcomes [3]. In the DCE survey, participants were repeatedly asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia deserves the most a treatment. The two hypothetical patients presented different levels of risk for five sarcopenia outcomes (i.e., the “attributes”): quality of life, mobility, domestic activities, fatigue and falls. More information regarding the full methodology of attributes and level selections for the sarcopenia outcomes presented in the choice sets can be found in previous publications [3, 6]. Briefly, a literature review, an expert consultation, a focus group with participants suffering from sarcopenia and an expert meeting have been conducted to identify both the attributes and the levels relevant for the DCE. Attributes and levels included in the DCE are displayed in Table 1. Two versions of the questionnaire were randomly proposed to participants. A total of 24 choice tasks were designed and blocked into these 2 versions containing 12 choice tasks each. An example of choice set is presented in Fig. 1. A dominance test, i.e., a choice set with one hypothetical patient who has clearly better outcomes than the other, was added to the questionnaire to assess the reliability of respondents’ choices. Patients who failed the dominance test were excluded from the analyses. The full questionnaire is available on request to the corresponding author.

Sarcopenia experts involved in the present DCE were recruited, in 2019, among experts from the Special Interest Group in Sarcopenia from the European Geriatric Medicine Society (EUGMS). The SIG comprised 84 international European and non-European healthcare professionals, e.g., medical doctors specialized in geriatrics, nutrition or physical rehabilitation, as well as researchers working in the field of sarcopenia. Participants were invited by email and the DCE questionnaire was developed in an online self-administered format using Qualtrics (Qualtrics, Provo, UT, USA). Data on participants’ demographics and socioeconomic characteristics were collected, e.g., sex, age, workplace, specialization and year of experience.

Data analysis was carried out using Nlogit software, version 5.0. In line with the patients DCE, a mixed logit panel model was used to estimate the relative importance of each DCE attribute for the experts. Standard deviation significantly different from zero was interpreted as evidence of significant preference heterogeneity for the attributes and levels in the sample. The relative importance of each outcome was calculated by dividing the attribute-specific level range by the sum of all attribute level ranges.

### Results

Among 84 members of the SIG sarcopenia group of the EUGMS, 37 (44.0%) completed the questionnaire, but 4 participants failed the dominance test and were, therefore, excluded. The remaining 33 respondents were gender balanced with 51.5% being female and 48.5% being male. The majority of the respondents were medical doctors (66.7%), while some researchers (24.2%) as well as Ph.D. students in the field of sarcopenia (9.1%) also completed the survey. The median professional experience of experts was 9 years (3–15 years). Experts were recruited from various countries in Europe and across the world: Belgium (n = 6), France (n = 3), Germany (n = 1), Italy (n = 1), Netherlands (n = 2),

| Table 1 | Attributes and levels included in the DCE |
|---------|----------------------------------------|
| Attributes | Levels |
| Patient’s mobility | Outdoor mobility without difficulties |
| Patient’s quality of life | Good |
| Patient’s management of domestic activities | Manages without difficulties |
| Patient’s level of fatigue | Not at all tired |
| Frequency of falls | Never |

| Attributes | Levels |
|------------|--------|
| Patient’s mobility | Outdoor mobility without difficulties |
| Indoor mobility only |
| Chairbound or bedbound |
| Patient’s quality of life | Good |
| Fair |
| Poor |
| Patient’s management of domestic activities | Manages without difficulties |
| Manages with difficulty |
| Unable |
| Patient’s level of fatigue | Not at all tired |
| Moderately tired |
| Tired very easily |
| Frequency of falls | Never |
| Occasional (once in the last 6 mo) |
| Frequent (2 or more times in the last 6 mo) |
Poland \((n = 1)\), Spain \((n = 4)\), Sweden \((n = 1)\), Switzerland \((n = 3)\), Turkey \((n = 5)\), Czech Republic \((n = 1)\), UK \((n = 1)\), Australia \((n = 1)\), Saudi Arabia \((n = 1)\) and USA \((n = 2)\).

Results of the mixed logit model are reported in Table 2. All five pre-selected sarcopenia outcomes were statistically significant, and thus, important for experts. The signs of coefficient were as expected, and the standard deviations were significant for patients’ mobility, patients’ management of domestic activities and frequency of falls, indicating variability in the respondents’ preferences. Overall, the most important sarcopenia outcome for experts was falls \((27\%)\) followed by patient’s management of domestic activities and patient’s mobility \((24\%)\), patient’s quality of life \((15\%)\) and fatigue \((10\%)\).

**Discussion**

This DCE study highlights that experts valued falls as the most relevant outcome. Compared to a similar study conducted with patients suffering from sarcopenia, some differences in the relative importance of sarcopenia outcomes were observed. Experts considered falls as more important than patients did \((27\% \text{ versus } 18\%)\), while fatigue \((10\% \text{ versus } 17\%)\) and mobility \((24\% \text{ versus } 30\%)\) were less important for experts. Both experts and patients seem, however, concordant about the level of importance of quality of life and the ability of managing domestic activities as outcomes of sarcopenia.

Different reasons could explain the differences between experts and patients on outcome ranking. Falls, for example, could have been considered more important by experts as they are well aware of the potential burden of falls from the perspective of the individual as well as from a public health point of view. Falls can be dramatic and have been shown to increase the risk of injuries, hospitalization, institutionalization, healthcare costs, and death \([7–9]\). They are also related to a reduction of quality of life, which could partially explain their higher ranking. Indeed, quality of life could be considered as a consequence of other outcomes \([10]\). Falls may be regarded as an objective clinical outcome that could be measured in future studies.

Patients, on the other side, seem to be more concerned about outcomes that directly impact their daily life, such as fatigue or mobility limitations, which can restrict themselves with regards to their independence, social interactions and which can also directly or indirectly impact other outcomes such as the ability to perform domestic activities and quality of life \([11]\). Fatigue was a more important outcome for patients, but showed the lowest ranking among experts. Fatigue related to sarcopenia may be considered by clinicians as a natural consequence of sarcopenia without a major impact on individual health or society. When the five outcomes were generated from the literature review, the patients’ perspective and the experts’ perspective, this outcome was not identified at all by the experts’ panel, probably because of the highly subjective nature of this outcome that is only felt by the patients themselves.
To our knowledge, this study provides the first assessment of experts’ preferences on sarcopenia outcomes and it revealed some differences between experts and patients. Results of such DCE identifying the most relevant outcomes of sarcopenia could be useful for the choice of primary and secondary endpoints of future interventional studies [12]. As experts and patients assigned different priorities to outcomes of sarcopenia, it is highly important to take both perspectives into account.

However, some potential limitations of this study exist. First, only a restricted sample size of experts was included, which could limit the generalizability of our results. Even if there is no specific power size recommended for conducting DCE, de Bekker-Grob [13] published a review in 2015 that showed among a sample of 69 DCEs performed in Healthcare, that a mean of 100–300 respondents is often targeted for DCE, which is noticeably higher than our sample size. Despite a moderate sample size, we nevertheless tried to be as much representative as possible by including heterogeneous profiles of experts from different European and non-European countries. Second, DCEs are evaluating hypothetical options. It is, therefore, impossible to guarantee that responders will apply their choices in real life.

### Table 2 Results from the Panel Mixed Logit Model

| Attributes and levels | Estimate (95% CI) | Standard deviation | Relative importance (%) |
|-----------------------|------------------|--------------------|------------------------|
| **Patient’s mobility** |                  |                    | 24%                    |
| Outdoor mobility without difficulties | $-1.59 (-2.53;-0.66)$** | 1.11* | |
| Outdoor mobility with difficulties | $0.81 (0.05;1.58)$* | 1.27** | |
| Indoor mobility only | $0.66 (-0.03;1.36)$ | 0.51 | |
| Chairbound/bedbound | $0.1179 (-0.93;1.17)$ | | |
| **Patient’s quality of life** |                  |                    | 15%                    |
| Good | $-0.82 (-1.37;-0.27)$** | 0.39 | |
| Fair | $0.12 (-0.25;0.49)$ | | |
| Poor | $0.70 (0.18;1.2)$** | 0.43 | |
| **Patient’s management of domestic activities** |                  |                    | 24%                    |
| Manages without difficulties | $-1.61 (-2.52;-0.71)$** | 0.57 | |
| Manages with difficulty | $0.79 (0.16;1.41)$* | | |
| Unable | $0.82 (0.19;1.46)$* | 0.84** | |
| **Patient’s level of fatigue** |                  |                    | 10%                    |
| Not at all tired | $-0.52 (-1.01;0.02)$* | 0.19 | |
| Moderately tired | $-0.03 (-0.36;0.29)$ | | |
| Tired very easily | $0.54 (0.01;1.07)$* | 0.01 | |
| **Frequency of falls** |                  |                    | 27%                    |
| Never | $-1.40 (-2.25;-0.56)$** | 0.67** | |
| Occasional (once in the last 6 months) | $0.02 (-0.43;0.47)$ | | |
| Frequent (2 or more times in the last 6 months) | $1.38 (0.58;2.18)$** | 0.77** | |

* $P < 0.05$
** $P < 0.01$

### Conclusion

Sarcopenia experts and patients suffering from sarcopenia assigned different priorities to outcomes associated with this condition. This discordance highlights the importance of considering both perspectives for the choice of primary and secondary outcomes in future intervention trials.

### Funding

None.

### Data availability

Under request to the corresponding author.

### Code availability

Under request to the corresponding author.

### Compliance with ethical standards

#### Conflict of interest

This work was supported by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). The authors do not have any conflict of interests to declare.

#### Human and animal rights

Approval for this study was obtained from the Medical Ethics Committee of the University of Liège, which coordinated the project (B707201834932).
Informed consent  No informed consent was necessary (data were collected using an anonymous online survey). Taking part into the survey was considered as a consent.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. https://doi.org/10.1093/ageing/afy169
2. Beaudart C, Zaaria M, Pasleau F et al (2017) Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS ONE 12:e0169548. https://doi.org/10.1371/journal.pone.0169548
3. Hiligsmann M, Beaudart C, Bruyère O et al (2019) Outcome priorities for older persons with sarcopenia. J Am Med Dir Assoc. https://doi.org/10.1016/j.jamda.2019.08.026
4. Harrison M, Milbers K, Hudson M et al. (2017) Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open. doi: https://doi.org/10.1136/bmjopen-2016-014719
5. Johnson FR, Hauber AB, Özdemir S et al (2010) Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn’s disease management. J Manag Care Pharm 16:616–628. https://doi.org/10.18553/jmcp.2010.16.8.616
6. Beaudart C, Bruyère O, Cruz-Jentoft AJ et al (2019) Patient’s engagement in the identification of critical outcomes in Sarcopenia. J Am Med Dir Assoc. https://doi.org/10.1016/j.jamda.2019.09.004
7. Clegg DO, Reda DJ, Harris CL et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354:795–808
8. Hartholt KA, Van Beeck EF, Polinder S et al (2011) Societal consequences of falls in the older population: Injuries, healthcare costs, and long-term reduced quality of life. J Trauma—Inj Infect Crit Care 71:748–753. https://doi.org/10.1097/TA.0b013e3181f655e5
9. Ahmed T, Curcio CL, Auais M et al (2020) Falls and life-space mobility: longitudinal analysis from the international mobility in aging study. Aging Clin Exp Res. https://doi.org/10.1007/s40520-020-01540-0
10. Beaudart C, Biver E, Bruyère O et al (2018) Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res 30:413–418. https://doi.org/10.1007/s40520-017-0794-8
11. Musich S, Wang SS, Ruiz J et al (2018) The impact of mobility limitations on health outcomes among older adults. Geriatr Nurs (Minneap) 39:162–169. https://doi.org/10.1016/j.gerinurse.2017.08.002
12. Reginster JY, Beaudart C, Al-Daghri N, et al (2021) Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clin Exp Res 33:3–17. https://doi.org/10.1007/s40520-020-01663-4
13. de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA (2015) Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient—Patient-Centered Outcomes Res 8:373–384. https://doi.org/10.1007/s40271-015-0118-z

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.